Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Oct 30;12(1):162.
doi: 10.1186/s13148-020-00954-x.

Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study

Jianping Wang  1 , Side Liu  2 , Hui Wang  3 , Lei Zheng  4 , Changchun Zhou  5 , Guoxin Li  6 , Rongkang Huang  3 , Huaiming Wang  3 , Chujun Li  7 , Xinjuan Fan  8 , Xinhui Fu  9 , Xinying Wang  10 , Hongliang Guo  11 , Jie Guan  11 , Yanlai Sun  11 , Xilin Song  11 , Zengjun Li  12 , Dianbin Mu  13 , Jujie Sun  13 , Xianglin Liu  14 , Yan Qi  14 , Feng Niu  14 , Chunhua Chen  14 , Xiaolin Wu  14 , Xianshu Wang  14 , Xianrang Song  15 , Hongzhi Zou  16   17
Affiliations
Clinical Trial

Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study

Jianping Wang et al. Clin Epigenetics. .

Abstract

Background and aims: Stool DNA testing is an emerging and attractive option for colorectal cancer (CRC) screening. We previously evaluated the feasibility of a stool DNA (sDNA) test of methylated SDC2 for CRC detection. The aim of this study was to assess its performance in a multicenter clinical trial setting.

Methods: Each participant was required to undergo a sDNA test and a reference colonoscopy. The sDNA test consists of quantitative assessment of methylation status of SDC2 promoter. Results of real-time quantitative methylation-specific PCR were dichotomized as positive and negative, and the main evaluation indexes were sensitivity, specificity, and kappa value. All sDNA tests were performed and analyzed independently of colonoscopy.

Results: Among the 1110 participants from three clinical sites analyzed, 359 and 38 were diagnosed, respectively, with CRC and advanced adenomas by colonoscopy. The sensitivity of the sDNA test was 301/359 (83.8%) for CRC, 16/38 (42.1%) for advanced adenomas, and 134/154 (87.0%) for early stage CRC (stage I-II). Detection rate did not vary significantly according to age, tumor location, differentiation, and TNM stage, except for gender. The follow-up testing of 40 postoperative patients with CRC returned negative results as their tumors had been surgically removed. The specificity of the sDNA test was 699/713 (98.0%), and unrelated cancers and diseases did not seem to interfere with the testing. The kappa value was 0.84, implying an excellent diagnostic consistency between the sDNA test and colonoscopy.

Conclusion: Noninvasive sDNA test using methylated SDC2 as the exclusive biomarker is a clinically viable and accurate CRC detection method.

Chinese clinical trial registry: Chi-CTR-TRC-1900026409, retrospectively registered on October 8, 2019; http://www.chictr.org.cn/edit.aspx?pid=43888&htm=4 .

Keywords: Advanced adenoma; Colorectal cancer; Methylation; Stool DNA test.

PubMed Disclaimer

Conflict of interest statement

Xianglin Liu, Yan Qi, Feng Niu, Chunhua Chen, Xiaolin Wu, Xianshu Wang, and Hongzhi Zou are current employees from Creative Biosciences (Guangzhou) CO., Ltd. No potential conflicts of interests were disclosed by the other authors.

Figures

Fig. 1
Fig. 1
The flowchart of study design. * An independent set of 103 patients discussed in the manuscript
Fig. 2
Fig. 2
Amplification by real-time qMSP of ACTB control, methylated, and unmethylated SDC2
Fig. 3
Fig. 3
a Levels of methylated SDC2 in 713 normals, 38 advanced adenomas (AA), and 359 CRCs. b ROC curves of the sDNA testing of SDC2 methylation for the detection of CRC and advanced adenomas
See this image and copyright information in PMC

References

    1. Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30(1):1–12. doi: 10.21147/j.issn.1000-9604.2018.01.01. - DOI - PMC - PubMed
    1. International Agency for Research on Cancer. China source: Globocan 2018[R/OL]. [2019‐8‐1]. https://gco.iarc.fr/today/data/factsheets/populations/160‐china‐fact‐she....
    1. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi: 10.1126/science.1235122. - DOI - PMC - PubMed
    1. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–573. doi: 10.1002/cncr.24760. - DOI - PMC - PubMed
    1. Siegel RL, Miller KD, Sauer AG, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020 doi: 10.3322/caac.21601. - DOI - PubMed

Publication types

MeSH terms